HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 05, May 2017 – Insights Into the Brain & microRNAs       » Omega-3 Therapy May Help Reverse Type 1 Diabetes       » The Potential of Saving Human Lives with Hibernation       » Scientists Unlock TCM Drug's Role in Weight Loss       » Medical Reforms in Beijing       » Fruits and Vegetables' Latest Superpower? Lowering Blood Pressure      
EYE ON CHINA
Epigenomics signs licensing and supply agreement with Kindstar for Epi proLung in China
Epigenomics AG, a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics Co. Ltd., a leading Chinese clinical diagnostics company, have entered into a licensing and supply agreement for Epigenomics' Epi proLung® tissue assay for the Chinese market.

Under the terms of the agreement Kindstar will commercialize the Epi proLung® assay for use in lung cancer diagnosis in China. Epigenomics will retain the responsibility to manufacture and supply the product and to provide support with respect to medical and regulatory considerations.

Noel Doheny, CEO of Epigenomics' US subsidiary, commented: "We are excited to enter into this agreement regarding our Epi proLung® tissue assay with Kindstar. The ability to leverage the established know-how and existing and well-functioning reference laboratory infrastructure of our new partner will provide a significant advantage for Epigenomics in the market introduction and technology roll-out of Epi proLung® in China. This agreement allows for a dual commercialization effort to apply Epigenomics' patented methods and its biomarker for lung cancer diagnosis in the Chinese market."

"Epigenomics' Epi proLung® assay fills an unmet need in current lung cancer diagnosis," added Shiang Huang, M.D., CEO of Kindstar. "We are very pleased to add Epi proLung® to the suite of cancer testing services we offer to Chinese physicians. We look forward to collaborating with Epigenomics on this assay and to the opportunity to expand our partnership on additional tests for the Chinese market."

Click here for the complete issue.

NEWS CRUNCH  
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Rare Diseases
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy